Cash shortage hurts Mich. biotech, drug-discovery firms

02/5/2009 | Ann Arbor Business Review (Mich.)

Dwindling support from venture capitalists and other funding sources in Michigan is slowing the growth of drug-discovery companies and forcing some biotech businesses to turn further to offering services, industry observers said. David Canter, who used to head Pfizer's operation in Ann Arbor, Mich., said discovery firms could benefit from increased activity in pharmaceutical services, and the state should keep on being an "idea factory" for the life sciences sector.

View Full Article in:

Ann Arbor Business Review (Mich.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
Nationwide, SL_Nationwide
Finance Manager - ENT
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA